GeneDx (NASDAQ:WGS) CEO Katherine Stueland Sells 10,501 Shares of Stock

GeneDx Holdings Corp. (NASDAQ:WGS) CEO Katherine Stueland sold 10,501 shares of GeneDx stock in a transaction that occurred on Tuesday, June 16th. The stock was sold at an average price of $60.77, for a total transaction of $638,145.77. Following the completion of the sale, the chief executive officer owned 104,372 shares of the company’s stock, valued at $6,342,686.44. This trade represents a 9.14% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Katherine Stueland also recently made the following trade(s):

• On Tuesday, June 9th, Katherine Stueland sold 3,639 shares of GeneDx stock. The shares were sold at an average price of $53.77, for a total transaction of $195,669.03.
• On Wednesday, April 29th, Katherine Stueland sold 2,172 shares of GeneDx stock. The stock was sold at an average price of $65.19, for a total transaction of $141,592.68.
• On Thursday, March 26th, Katherine Stueland sold 46,933 shares of GeneDx stock. The stock was sold at an average price of $63.17, for a total transaction of $2,964,757.61.

GeneDx Trading Up 4.6%

NASDAQ:WGS opened at $59.01 on Friday. The company has a market capitalization of $1.75 billion, a P/E ratio of -22.02 and a beta of 1.96. The company has a current ratio of 3.09, a quick ratio of 2.95 and a debt-to-equity ratio of 0.38. GeneDx Holdings Corp. has a 12 month low of $32.21 and a 12 month high of $170.87. The firm has a fifty day simple moving average of $54.38 and a 200-day simple moving average of $86.68.

GeneDx (NASDAQ:WGS) last released its earnings results on Monday, May 4th. The company reported ($0.28) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.06) by ($0.22). The firm had revenue of $102.25 million during the quarter, compared to analyst estimates of $112.46 million. GeneDx had a negative net margin of 17.58% and a positive return on equity of 9.15%. During the same period in the previous year, the company earned ($0.23) earnings per share. On average, equities research analysts anticipate that GeneDx Holdings Corp. will post -1 earnings per share for the current year.

GeneDx News Roundup

Here are the key news stories impacting GeneDx this week:

• Positive Sentiment: GeneDx appointed Mark Gardner as its new company president, a leadership change that could help execution and strategic focus. GeneDx Appoints Mark Gardner as New Company President
• Neutral Sentiment: The company disclosed insider stock sales by CEO Katherine Stueland and CFO Kevin Feeley, but the filings say the shares were sold to meet tax withholding obligations tied to equity vesting. SEC filing for CEO sale SEC filing for CFO sale
• Negative Sentiment: Multiple law firms are promoting a securities class action against GeneDx, alleging investors were misled about the Fabric Genomics acquisition and related performance issues, with a lead-plaintiff deadline of August 3, 2026. Class action lawsuit notice
• Negative Sentiment: The lawsuit coverage highlights the company’s prior earnings disappointment and the large May 2026 stock decline, keeping pressure on investor confidence. Hagens Berman class action article

Wall Street Analyst Weigh In

WGS has been the subject of several research analyst reports. Wall Street Zen cut GeneDx from a “hold” rating to a “sell” rating in a research note on Saturday, May 9th. Weiss Ratings lowered GeneDx from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Monday, June 1st. Wells Fargo & Company reiterated an “overweight” rating and issued a $75.00 price target (down from $155.00) on shares of GeneDx in a report on Tuesday, May 5th. Guggenheim reduced their price target on shares of GeneDx from $100.00 to $70.00 and set a “buy” rating for the company in a research report on Tuesday, May 5th. Finally, Canaccord Genuity Group set a $75.00 price objective on shares of GeneDx and gave the company a “buy” rating in a research note on Tuesday, May 5th. Six equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, GeneDx currently has a consensus rating of “Moderate Buy” and an average target price of $96.43.

Hedge Funds Weigh In On GeneDx

A number of institutional investors have recently modified their holdings of WGS. Royal Bank of Canada lifted its holdings in shares of GeneDx by 30.2% in the 1st quarter. Royal Bank of Canada now owns 29,479 shares of the company’s stock valued at $2,611,000 after buying an additional 6,840 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its stake in shares of GeneDx by 6.3% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 7,641 shares of the company’s stock worth $677,000 after buying an additional 453 shares during the last quarter. NewEdge Advisors LLC grew its holdings in GeneDx by 270,700.0% during the first quarter. NewEdge Advisors LLC now owns 2,708 shares of the company’s stock worth $240,000 after acquiring an additional 2,707 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its holdings in GeneDx by 67.5% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 28,224 shares of the company’s stock worth $2,500,000 after acquiring an additional 11,375 shares during the period. Finally, Cetera Investment Advisers purchased a new position in GeneDx during the second quarter valued at approximately $249,000. Hedge funds and other institutional investors own 61.72% of the company’s stock.

GeneDx Company Profile

GeneDx is a clinical diagnostics company specializing in comprehensive genetic and genomic testing for rare and inherited disorders. The company offers a broad portfolio of assays, including targeted gene panels, whole exome sequencing, whole genome sequencing and chromosomal microarray analysis. GeneDx’s laboratory services support the diagnosis of a wide range of conditions—from rare pediatric diseases and hereditary cancer syndromes to neuromuscular and metabolic disorders—by providing clinicians with detailed variant interpretation and reporting.

Founded in 2000 and based in Gaithersburg, Maryland, GeneDx was established with the aim of accelerating the translation of genomic discoveries into clinical care.